Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: GVC Down 18% As Chiefs Sell 3 Million Shares

Fri, 08th Mar 2019 10:50

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Fresnillo, up 1.7%. The Mexican gold miner was tracking spot gold price higher, quoted at USD1,295.07 an ounce, up from USD1,285.30 at the London equities close Thursday. Mid-cap Egyptian miner Centamin was up 1.8%.----------GlaxoSmithKline, up 0.8%. The drugmaker said the Atlas and Flair studies showed that along-acting, injectable two-drug regimen in HIV-1 patients had similar efficacy to a daily three-drug treatment. Both phase three studies assessed a long-acting, injectable combination of cabotegravir and rilpivirine - injected every four weeks - and compared it against a standard of care, daily, three-drug regimen. 48-week data from both studies shows that they met their primary endpoints, showing that the two-drug regimen was not inferior in treating HIV. John Pottage, chief scientific & medical officer Of ViiV Healcare said: "With Flair and Atlas, we now have positive results from two pivotal phase three studies demonstrating that this long-acting, once-monthly injectable regimen has similar efficacy, safety and tolerability to a daily oral three-drug regimen for the treatment of HIV."----------FTSE 100 - LOSERS----------GVC Holdings, down 18% at 563.65 pence. GVC Chair Lee Feldman and Chief Executive Kenneth Alexander sold a significant amount of stock. Alexander sold 2.1 million shares at 666 pence for GBP13.7 million, while Feldman disposed of 900,000 shares at the same price for GBP6.0 million. Alexander said: "We have both held large personal shareholdings in GVC for a long time and continue to do so. Both of us remain fully committed to GVC and, whilst I continue to have the support of our shareholders, I'm here for the long term and at the very least I have a current plan that will take three plus years to accomplish."----------FTSE 250 - WINNERS----------SIG, up 9.1%. The building products supplier reported a drop in annual revenue, though it swung to a pretax profit. SIG's statutory revenue fell to GBP2.74 billion in 2018, from GBP2.88 billion in 2017, but it returned to pretax profit, posting GBP28.5 million from a GBP54.7 million loss a year prior. On an underlying basis, revenue fell 1.2% to GBP2.68 billion, with like-for-like sales down 2.1%. SIG's underlying pretax profit was up 8.5% to GBP75.3 million. SIG is paying a 2.5p final dividend, meaning the total for 2018 is unchanged from the year before at 3.75p. The company said its transformation strategy is now beginning to take shape, with the second half of 2018 seeing "significant" progress.----------Bodycote, up 7.2%. The thermal processing firm reported solid revenue and profit growth for 2018, with all of its divisions managing to report revenue improvement. The firm's statutory pretax profit climbed to GBP132.2 million from GBP117.0 million, with the headline figure up 12% to GBP136.4 million. Bodycote's revenue rose 5.6%, and 6.7% at constant currency rates, to GBP728.6 million. The company will pay a final dividend of 13.2p, taking the 2018 total to 19.0p from 17.4p a year before. On top of that, it also will pay a special dividend of 20p, having returned a special payout of 25p in 2017. Bodycote had a strong year, the company said, and it enters 2019 "well positioned".----------FTSE 250 - LOSERS----------Saga, down 9.0%. JPMorgan downgraded Saga to Underweight from Neutral, saying a weak balance sheet, alongside heightened insurance industry competition, could lead to concerns about the over 50s travel and insurance services provider's dividend. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Panthera Resources, up 20%. The miner reported positive developments from an investee, including a "significant" acquisition. Panthera has a 17% stake in Anglo Saxony Mining, a European explorer and developer with a flagship tin project in Tellerhauser, Germany. ASM's purchase is the Gottesberg tin deposit, 28 kilometres to the west of Tellerhauser, paid with both cash and shares. Gottesberg has a total resource of 42.1 million tonnes of ore at a grade of 0.27% tin, suggesting 113,000 tonnes of the commodity. Combining Gottesberg and Tellerhauser's resources, ASM now has a resource of 217,000 ounces of tin, which Panthera said is among the largest in the world. ----------Debenhams, up 13%. The troubled department store chain said it is "disappointed" that Sports Direct International has decided to requisition a general meeting to appoint Sports Direct boss Mike Ashley to the Debenhams board and remove all but one current board member. Debenhams added it has been engaging with both Sports Direct and other stakeholders regarding options to restructure the company's balance sheet. Sports Direct late Thursday said Founder & Chief Executive Ashley is seeking appointment to Debehmans board of directors. Ashley is aiming to be appointed to an executive role to focus on Debenhams business, including building a strong board and management team. Furthermore, Sports Direct is seeking to oust all Debenhams' board members with the exception of Rachel Osborne, who became a director in September 2018. If appointed, Ashley would step down from his current roles as a director & CEO of Sports Direct, which was down 0.5%.----------OTHER MAIN MARKET AND AIM - LOSERS----------Goals Soccer Centres, down 28%. The five-a-side football pitch operator said it expects 2018 results to be "materially below" expectations following discovery of accounting errors. Goals explained that results for the full year are now expected to be "materially below expectations" and delayed from their originally planned reporting date of March 12. This follows the firm - alongside its auditors - having to resolve some "accounting errors". Goals emphasised that the "majority" of these expected accounting adjustments are "non-cash" in nature. Despite this, the changes would mean that the firm will have "exceeded one of its banking covenants". Goals is currently discussing with the bank to agree new, renegotiated facilities. For the first two months of 2019, Goals reported trading had been "strong" with an increases in like-for-like sales on the prior year in both the UK and US.----------

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.